Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT07206290

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07206290
  • EU CT 2025-523184-37-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07206290. Randomized; double masking; primary purpose treatment. Start 2026-03-02 (anticipated); primary completion 2027-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
Acronym
ARTIST-CKD
Intervention (Drug)
Survodutide (BI 456906)
Intervention (Drug)
Placebo
Lead sponsor
University Medical Center Groningen (class: other)

Record details

Record id
cardio:ct-nct07206290
Content hash
d88258f661c447315d0fc5c19097e511ffec73277aa83b2ddaa0d9bb6196c518